Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Goyang-si
Clinical trial register · South Korea

Clinical Trials in Goyang-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 195 Goyang-si 72 Daegu 59 Seongnam-si 59 Busan 50
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca72 Merck Sharp & Dohme LLC29 National Cancer Center, Korea23 Janssen Research & Development, LLC20 Hoffmann-La Roche19 Clear sponsor filter
Site location
Seoul195 Goyang-si72 Daegu59 Seongnam-si59 Busan50
All 52 locations
Target enrolment
to

Trials with a site in Goyang-si

72 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Goyang-si, Seoul
2026-09-29
Recruiting
BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA
NCT07570394Chronic Obstructive Pulmonary Disease (COPD), Asthma
AstraZeneca
Observational
600
Chuncheon, Daegu, Goyang-si, Gwangmyeong, Jinju, Seongnam-si, Seoul, Wŏnju
2026-09-17
Recruiting
AstraZeneca
Phase 3
950
Busan, Daegu, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul, Yangsan
2026-09-16
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Recruiting
AstraZeneca
Phase 3
2,000
Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Yangsan
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon
2026-06-29
Recruiting
AstraZeneca
Phase 3
150
Cheonan-si, Daegu, Goyang-si, Hwasun-eup, Incheon, Seongbuk-Gu, Seongnam-si, Seoul
2026-06-15
Recruiting
AstraZeneca
Phase 3
670
Goyang-si, Seoul
2026-05-04
Recruiting
AstraZeneca
Phase 3
1,100
Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan
2025-12-29
Recruiting
AstraZeneca
Phase 3
400
Goyang-si, Incheon, Seoul, Suwon
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Bukgu, Goyang-si, Seoul
2025-10-30
Recruiting
AstraZeneca
Observational
130
Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon
2025-10-15
Recruiting
AstraZeneca
Phase 3
700
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2025-08-06
Recruiting
AstraZeneca
Phase 3
800
Goyang-si, Gwangjin-gu, Seoul, Songpa-gu, Suwon
2025-08-01
Recruiting
AstraZeneca
Phase 3
15,100
Bucheon-si, Busan, Changwon-si, Daegu, Daejeon, Goyang-si, Gwangju, Gwangmyeong
2025-06-04
Recruiting
AstraZeneca
Phase 3
1,220
Busan, Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
2025-05-06
Recruiting
AstraZeneca
Phase 3
600
Goyang-si, Seoul, Suwon
2025-03-27
Recruiting
AstraZeneca
Phase 3
5,000
Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Daegu, Goyang-si, Gyeonggi-do, Jeonnam, Seoul
2025-03-01
Recruiting
AstraZeneca
Phase 3
744
Busan, Chungcheongbuk-do, Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2024-10-04
Recruiting
AstraZeneca
Phase 3
1,018
Busan, Goyang-si, Jeonnam, Seoul
2024-08-07
Recruiting
AstraZeneca
Phase 3
582
Goyang-si, Namdong-gu, Seoul, Suwon
2024-04-29
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Recruiting
AstraZeneca
Phase 3
1,145
Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Daegu, Goyang-si, Seongnam, Seoul
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,835
Ansan-si, Busan, Cheonan-si, Daegu, Goyang-si, Seoul
2023-11-07
Active, closed
AstraZeneca
Phase 3
5,511
Cheonan-si, Daegu, Goyang-si, Seongnam-si, Seoul
2023-10-05
Recruiting
AstraZeneca
Phase 3
800
Daegu, Goyang-si, Gyeonggi-do, Seoul
2023-09-22
Active, closed
AstraZeneca
Phase 3
37
Cheongju-si, Goyang-si, Seongnam-si, Seoul, Tonggu
2023-05-08
Recruiting
AstraZeneca
Phase 3
4,300
Busan, Daegu, Donggu, Goyang-si, Jeonnam, Seongbuk-Gu, Seoul
2023-03-31
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Active, closed
AstraZeneca
Phase 3
1,174
Busan, Daegu, Goyang-si, Seongnam-si, Seoul
2022-11-28
Active, closed
AstraZeneca
Phase 3
341
Goyang-si, Gyeonggi-do, Jinju, Seoul, Suwon
2022-08-03
Active, closed
AstraZeneca
Phase 3
760
Busan, Daegu, Goyang-si, Junggu, Seoul
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Bukgu, Busan, Goyang-si, Seoul
2022-03-25
Active, closed
AstraZeneca
Phase 3
791
Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2022-02-18
Active, closed
AstraZeneca
Phase 3
148
Daejeon, Goyang-si, Incheon, Seoul
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Goyang-si, Seoul
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
Goyang-si, Seoul
2021-10-18
Active, closed
AstraZeneca
Phase 3
712
Busan, Goyang-si, Incheon, Seongnam-si, Seoul
2021-08-05
Active, closed
AstraZeneca
Phase 3
315
Cheonan-si, Daegu, Goyang-si, Seongnam-si, Seoul
2021-06-30
Active, closed
AstraZeneca
Phase 3
893
Goyang-si, Seoul
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,157
Cheonan-si, Daegu, Goyang-si, Seoul
2021-04-26
Recruiting
AstraZeneca
Phase 1
304
Cheongju-si, Goyang-si, Jinju, Seoul
2021-03-09
Active, closed
AstraZeneca
Phase 3
1,371
Busan, Daegu, Goyang-si, Seoul
2021-01-28
Active, closed
AstraZeneca
Phase 3
370
Busan, Cheongju-si, Goyang-si, Seongnam-si, Seoul
2020-10-02
Active, closed
AstraZeneca
Phase 3
866
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2020-07-24
Active, closed
AstraZeneca
Phase 3
1,012
Daegu, Goyang-si, Seongnam-si, Seoul
2020-07-13
Active, closed
AstraZeneca
Phase 3
805
Goyang-si, Seoul, Suwon, Yangsan
2020-05-05
Active, closed
AstraZeneca
Phase 2
240
Goyang-si, Incheon
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon
2020-04-16
Active, closed
AstraZeneca
Phase 3
587
Cheongju-si, Goyang-si, Seoul
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2019-06-25
Active, closed
AstraZeneca
Phase 3
724
Cheongju-si, Goyang-si, Gyeonggi-do, Seoul
2019-03-06
Active, closed
AstraZeneca
Phase 2
367
Goyang-si, Seongnam-si, Seoul, Suwon
2019-01-09
Active, closed
AstraZeneca
Phase 3
1,407
Goyang-si, Seongnam-si, Seoul, Suwon
2019-01-04
Active, closed
AstraZeneca
Phase 2
401
Dongjakgu, Goyang-si, Seodaemun-gu, Seoul, Suweonsi Paldalgu
2018-12-21
Active, closed
AstraZeneca
Phase 3
724
Busan, Daegu, Goyang-si, Seoul
2018-11-30
Active, closed
AstraZeneca
Phase 3
1,063
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Daegu, Goyang-si, Seoul
2018-10-31
Active, closed
AstraZeneca
Phase 3
730
Changwon-si, Cheongju-si, Daegu, Goyang-si, Jinju, Seongnam-si, Seoul, Suwon
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Goyang-si, Incheon, Seoul, Suwon
2018-09-27
Active, closed
AstraZeneca
Phase 2
273
Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2018-03-07
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Daejeon, Goyang-si, Hwasun-gun, Incheon, Seoul
2017-07-25
Active, closed
AstraZeneca
Phase 1/2
264
Goyang-si, Seongnam-si, Seoul
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Goyang-si, Seongnam-si, Seoul
2014-10-31
Active, closed
AstraZeneca
Phase 1
344
Cheongju-si, Goyang-si, Seongnam-si, Seoul
2014-08-05
Active, closed
AstraZeneca
Phase 3
1,837
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2014-04-22
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Goyang-si, Seoul
2013-08-26
Rows per page Showing 1–72 of 72
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/goyang-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 72 of those studies with a site in Goyang-si that also match the filters currently applied.

How many clinical trials are recruiting in Goyang-si?

26 of the 72 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 45 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Goyang-si), 72 studies
PhaseStudiesRecruitingShare
Phase 3612384.7%
Phase 2506.9%
Phase 1314.2%
Observational222.8%
Phase 1/2101.4%

Most active sponsors

Lead sponsors with the most studies (Goyang-si)
Lead sponsorStudiesRecruiting
AstraZeneca7226
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.